#Foundayo

Foundayo is Eli Lilly's brand name for orforglipron, the first small-molecule GLP-1 pill approved for obesity. The FDA cleared it in early April 2026; the IQVIA launch tracker has stepped up from 3,707 prescriptions in Week 2 to 5,612 in Week 3 to 7,335 in Week 4 (the week ending May 1, per Citi's May 8 client note). Citi flagged that the IQVIA data captures retail and partial telehealth, likely understating Lilly Direct and the 12+ telehealth firms that account for roughly 35% of launch volume — Lilly executives have cited 20,000 patients now on the drug. Citi modeled $146M in Q2 and $1.6B for full-year 2026. On the April 30 Q1 call, Lilly disclosed more than 8,000 prescribers (one-third writing an oral GLP-1 for the first time) and 80% of patients new to the GLP-1 class — with commercial access confirmed at two of the three largest US PBMs effective mid-May.

The ACHIEVE-3 obesity Phase 3 gave Foundayo HbA1c superiority versus oral semaglutide in type-2 diabetes, but indirect comparisons published just after launch suggested oral Wegovy may produce greater weight loss with fewer GI discontinuations. Managed Healthcare Executive's head-to-head writeup framed the choice as HbA1c lead versus weight-loss lead. On May 4, an FAERS hepatic-failure case in a 56-year-old male — logged April 30 — surfaced publicly. LLY fell 3% premarket before recovering as Lilly released updated safety data the FDA had requested, citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program. RBC Capital framed the case as 'baseline noise' and pointed to comparable hepatic-failure tallies for Mounjaro (30), Ozempic (33), Wegovy (15), and Zepbound (2).

Stories here cover prescription volumes, payer coverage, head-to-head comparisons with oral Wegovy, and side-effect signals from FAERS. See #orforglipron for the underlying molecule and #oral-glp-1 for class context.